ProfileGDS5678 / 1433439_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 90% 90% 88% 90% 91% 86% 89% 89% 88% 89% 91% 90% 89% 89% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.104590
GSM967853U87-EV human glioblastoma xenograft - Control 27.1817190
GSM967854U87-EV human glioblastoma xenograft - Control 36.945188
GSM967855U87-EV human glioblastoma xenograft - Control 47.3038690
GSM967856U87-EV human glioblastoma xenograft - Control 57.5089191
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.2963686
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.8511689
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 37.0617989
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.8801588
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.0783589
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.275991
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.2783290
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.0200989
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.0812789